We have also previously reported on the therapeutic effect of ZSYM73-ABD in a murine AD model with promising results, and since ABD is cross reactive to MSA, this is further indication that albumin-binding has no dramatic negative effect on target binding. This evidence concerns the gene ALB and Alzheimer disease.